Skip to main content
DRUG logo

DRUG · Bright Minds Biosciences Inc.

$71.13 -0.83 (-1.15%)
Market Cap
$706.08M
Shares
9.81M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$71.96 Open$72.11 Day$70.20–73.01 52W$31.80–123.75 Avg vol 30d302K Short int956K · 9.7% float · 3.1d Short vol68% DataMar 2021–Jul 2026

Up next

FQ4-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.2 · elevated Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg −0%
below
RSI (14) 49
neutral
MACD trend Negative
52-week position 44%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Weak
1-month return +9%
trailing
6-month return −8%
trailing
YTD return −8%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $72 › 200d $75 — 200d above 50d
Institutional flow Accumulating
7 of 93 funds reported for Jun 30 · net +93 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.74% of float · ▲ +0.3% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
93 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −38%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Neutral
Price vs 50-day avg
−0% Neutral
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
44% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $72 › 200d $75 — 200d above 50d
Institutional flow Accumulating
7 of 93 funds reported for Jun 30 · net +93 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.74% of float · ▲ +0.3% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
93 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $32 Now $72 · 44% 52-wk high $124
vs 200-day avg -5% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DRUG
Bright Minds Biosciences Inc.
this stock
$706.08M -7.8% 9.7%
ONC
BeOne Medicines Ltd.
$474.96B +8.8% +22179.2% 966.6 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$124.46B +8.2% +46.2% 29.1 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.88B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +3.7% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
95
% held
93.0%
Reported
7 of 93
Top holder
JANUS HENDERSON GROUP PLC
Held Float
View
Held by Funds
Fund positions
87
View
Short & Settlement
Short Interest Rising
Shares short
955.8K
Days to cover
3.1d
Change
+3.3K sh
View
Short Volume
Short vol %
68%
As of
Jul 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$64
As of
Jun 26, 2026
View
Off-Exchange
Off-exchange %
38.8%
Week of
May 4, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jun 3, 2026
This year
12
View
Exempt Offerings
Offering
$34.6M
Filed
Nov 19, 2024
View

Performance

5D 20D 120D MTD YTD
DRUG -3.6% +9.4% -8.5% +2.5% -7.8%
SPY -1.0% 0.0% +7.4% -0.8% +8.6%
vs SPY -2.6% +9.4% -15.9% +3.3% -16.4%
Key facts CIK 1827401 CUSIP 10919W405 13F (30d) 8 filings 8 filers Visit website Investor relations